// App-Quantinova.ai

9024 : Pembrolizumab vs docetaxel for previously treated advanced NSCLC with a PD-L1 tumor proportion score (TPS) 1%-49%: Results from KEYNOTE-010.

Researchers

Presenter

  • Edward B. Garon

Principal Investigators

  • Dong-Wan Kim

  • Enriqueta Felip

  • Jose Luis Perez-Gracia

  • Ji-Youn Han

  • Julian R. Molina

  • Joo-Hang Kim

  • Catherine Dubos Arvis

  • Myung-Ju Ahn

  • Margarita Majem

  • Mary J. Fidler

  • Matthew A. Gubens

  • Gilberto Castro

  • Marcelo Garrido

  • Yue Shentu

  • Ellie Im

  • Gregory M. Lubiniecki

  • Paul Baas

Medical Centers

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • Yale University School of Medicine and Yale Cancer Center, New Haven, CT

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Mayo Clinic, Rochester, MN

  • Centre Francois Baclesse, Caen, France

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Rush University Medical Center, Chicago, IL

  • University of California, San Francisco, San Francisco, CA

  • Instituto do Cancer do Estado de Sao Paulo - ICESP, Sao Paulo, Brazil

  • Departamento de Hemato-Oncologia, Pontificia Universidad Catolica de Chile, Santiago, Chile

  • Merck & Co., Inc., Kenilworth, NJ

  • Netherlands Cancer Institute (NKI), Amsterdam, Netherlands

Locations

  • Brazil

  • Netherlands

  • Spain

  • United States

  • France

  • Chile

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

  • Tissue polypeptide-specific antigen

Drug/Treatment

  • Pembrolizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01905657

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved